Literature DB >> 28501872

A Mechanism Study Underlying the Protective Effects of Cyclosporine-A on Lung Ischemia-Reperfusion Injury.

Jian''an Li1, Zhongya Yan, Qianjin Fang.   

Abstract

AIM: This study is aimed at validating the hypothesis that administration of cyclosporine-A (CsA) would be protective in lung ischemia-reperfusion (I/R) injury and in exploring the underlying mechanism.
METHODS: Rabbits were divided into 4 groups: the control, sham operation, I/R, and I/R with CsA treatment. Flow cytometry was used to measure the mitochondrial membrane potential. Laser scanning confocal microscope was used to analyze mitochondrion permeability transition pore (MPTP). The apoptotic cell was detected by the TUNEL staining. Western blot was performed to analyze the protein expression levels.
RESULTS: CsA not only attenuated the histopathologic alterations in lung and mitochondria after I/R injury, but also attenuated I/R injury through increasing MPP and inhibiting MPTP opening. Besides, CsA attenuated I/R injury through suppressing the release of cytochrome-c (CytC), inhibiting cell apoptosis and decreasing the expression levels of cyclophilin-D (Cyp-D), adenine nucleotide translocase 1 (ANT1) and voltage-dependent anion channel 1 (VDAC1). Finally, we found that Cyp-D knockdown inhibits I/R injury-induced MPTP opening and cell apoptosis.
CONCLUSION: Our study found that the protective role of CsA on lung I/R injury depends on the inhibition of MPTP and CytC release, suppression of the activation of mitochondrial apoptosis pathway and the expressions of apoptotic-related proteins, as well as the decreased expression levels of ANT1 and VDAC1.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Cyclosporine-A; Lung ischemia-reperfusion injury; Mitochondrial permeability transition pore

Mesh:

Substances:

Year:  2017        PMID: 28501872     DOI: 10.1159/000458760

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  9 in total

Review 1.  Mitochondrial bioenergetics and pulmonary dysfunction: Current progress and future directions.

Authors:  Vadim S Ten; Veniamin Ratner
Journal:  Paediatr Respir Rev       Date:  2019-04-12       Impact factor: 2.726

Review 2.  Molecular mechanisms and consequences of mitochondrial permeability transition.

Authors:  Massimo Bonora; Carlotta Giorgi; Paolo Pinton
Journal:  Nat Rev Mol Cell Biol       Date:  2021-12-08       Impact factor: 113.915

3.  Cyclosporine A Plus Ischemic Postconditioning Improves Neurological Function in Rats After Cardiac Resuscitation.

Authors:  Xiang Zhou; YanLiang Qu; GuoShen Gan; ShuiBo Zhu; Yang Huang; Yong Liu; Jian Zhu; Biao Xie; ZhiTian Tan
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

4.  Cardiac ischemia/reperfusion stress reduces inner mitochondrial membrane protein (mitofilin) levels during early reperfusion.

Authors:  Nathalie Tombo; Abdulhafiz D Imam Aliagan; Yansheng Feng; Harpreet Singh; Jean C Bopassa
Journal:  Free Radic Biol Med       Date:  2020-07-26       Impact factor: 7.376

5.  Cyclosporine A prevents cardiac arrest-induced acute respiratory failure: a post-hoc analysis of the CYRUS trial.

Authors:  Louis Kreitmann; Laurent Argaud; Michel Ovize; Martin Cour
Journal:  Intensive Care Med       Date:  2020-04-21       Impact factor: 17.440

Review 6.  Cyclophilin D, Somehow a Master Regulator of Mitochondrial Function.

Authors:  George A Porter; Gisela Beutner
Journal:  Biomolecules       Date:  2018-12-14

Review 7.  Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology.

Authors:  Massimo Bonora; Simone Patergnani; Daniela Ramaccini; Giampaolo Morciano; Gaia Pedriali; Asrat Endrias Kahsay; Esmaa Bouhamida; Carlotta Giorgi; Mariusz R Wieckowski; Paolo Pinton
Journal:  Biomolecules       Date:  2020-07-04

8.  Effects of cyclosporin A pre-treatment combined with etomidate post-treatment on lung injury induced by limb ischemia-reperfusion in rats.

Authors:  Haibo Zou; Xiaofeng Sun
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

9.  Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?

Authors:  Martin Cour; Michel Ovize; Laurent Argaud
Journal:  Crit Care       Date:  2020-06-02       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.